BridgeBio Pharma Pre-Tax Profit Margin 2018-2024 | BBIO
Current and historical pre-tax profit margin for BridgeBio Pharma (BBIO) from 2018 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. BridgeBio Pharma pre-tax profit margin for the three months ending September 30, 2024 was .
| BridgeBio Pharma Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2024-09-30 |
$0.22B |
$-0.45B |
-204.59% |
| 2024-06-30 |
$0.22B |
$-0.46B |
-210.50% |
| 2024-03-31 |
$0.22B |
$-0.55B |
-249.32% |
| 2023-12-31 |
$0.01B |
$-0.65B |
-6530.00% |
| 2023-09-30 |
$0.01B |
$-0.62B |
-6240.00% |
| 2023-06-30 |
$0.01B |
$-0.59B |
-9750.00% |
| 2023-03-31 |
$0.08B |
$-0.43B |
-547.44% |
| 2022-12-31 |
$0.08B |
$-0.49B |
-621.79% |
| 2022-09-30 |
$0.09B |
$-0.50B |
-557.30% |
| 2022-06-30 |
$0.09B |
$-0.52B |
-568.13% |
| 2022-03-31 |
$0.07B |
$-0.62B |
-867.61% |
| 2021-12-31 |
$0.07B |
$-0.59B |
-849.28% |
| 2021-09-30 |
$0.06B |
$-0.57B |
-1016.07% |
| 2021-06-30 |
$0.06B |
$-0.54B |
-867.74% |
| 2020-09-30 |
$0.02B |
$-0.45B |
-2063.64% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.773B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
